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Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Trials of Vertebroplasty for Vertebral Fractures
To the Editor: In the August 6 issue, Kallmes et 
al.1 report on the Investigational Vertebroplasty 
Safety and Efficacy Trial (ClinicalTrials.gov num­
ber, NCT00068822), and Buchbinder et al.2 report 
on a randomized trial of vertebroplasty for pain­
ful osteoporotic vertebral fractures (Australian 
New Zealand Clinical Trials Registry number, 
ACTRN012605000079640). We have serious con­
cerns about both trials, which included patients 
with a duration of pain of up to 12 months. Verte­
broplasty provides internal fixation of nonhealed 
osteoporotic vertebral fractures. It is well estab­
lished that fixation of acute fractures elsewhere 
in the skeleton reduces fracture pain. Internal 
fixation of healed fractures is clearly inappropri­
ate. Osteoporotic vertebral fractures usually heal 
within 8 weeks, although  magnetic resonance 
imaging shows that edema persists longer. The 
study by Kallmes et al. involved outpatients ex­
clusively, so that inpatients hospitalized with 
acute fracture pain were excluded. Furthermore, 
the protocol mandated 4 weeks of medical ther­
apy before enrollment. This protocol effectively 
removed the entire population of patients with 
subacute fractures, resulting in a study on healed 
fractures. A more appropriate selection criterion 
would have been uncontrolled pain for less than 
6 weeks.3 In the  trial reported on by Buchbinder 
et al., the number of patients with pain for less 
than 6 weeks was far too small for a subgroup 
analysis.
The trial by Buchbinder et al. had a target en­
rollment of 200 patients, but 78 were enrolled 
over 4 years, substantially limiting statistical pow­
er.4 Although the study is described as a multi­
center trial, two of the four hospitals withdrew 
early from the study, after enrolling five patients 
each. A total of 68% of the procedures were 
performed in one hospital by one radiologist. 
The rates of eligible patients who declined to par­
ticipate were 64% in the trial reported on by Buch­
binder et al. and 70% in the trial reported on by 
Kallmes et al. (85% in the United States),5 raising 
further concerns regarding patient selection.
Neither of these articles can accurately com­
ment on the role of vertebroplasty in the control 
of subacute osteoporotic fracture pain. In Aus­
tralia, this is the most common reason for the 
procedure.
William Clark, M.D.
St. George Private Hospital 






Monash Medical Centre 
Melbourne, VIC, Australia
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To the Editor: Although the studies reported 
on by Kallmes et al. and Buchbinder et al. are 
invaluable additions to research in interventional 
radiology, we are concerned about the conclu­
sions that may be drawn from them, with the 
consequence that tens of thousands of patients 
may be denied a procedure that the vast majority 
of studies published to date have supported.
First, patients with maximal back pain tend 
to have the greatest improvement in pain score 
after vertebroplasty. Unfortunately, these patients 
would also be the least likely to participate in 
such studies and to risk being randomly assigned 
to the placebo group, as evidenced by the pre­
procedural pain scores among patients who were 
enrolled.
Second, neither study was sufficiently powered 
to perform subanalyses. We have found that pa­
tients with certain types of fractures (e.g., those 
with gas­filled clefts and pathologic fractures) 
are more likely to have improvement in pain 
scores after vertebroplasty. The studies were ei­
ther underpowered to evaluate these subgroups 
of patients (in the case of patients with fractures 
with clefts) or excluded them altogether (in the 
case of patients with pathologic fractures). Cer­
tainly, we would not advocate vertebroplasty in 
all patients with back pain due to compression 
fractures.
Mark Otto Baerlocher, M.D.
University of Toronto 
Toronto, ON, Canada 
mark.baerlocher@utoronto.ca
Peter L. Munk, M.D. 
David M. Liu, M.D.
Vancouver General Hospital 
Vancouver, BC, Canada
Dr. Munk reports receiving lecture fees from Cook Medical. 
No other potential conflict of interest relevant to this letter was 
reported.
To the Editor: Conclusions regarding the clini­
cal usefulness of vertebroplasty should be weighed 
against the limitations of the studies reported 
on by Buchbinder et al. and Kallmes et al. First, 
there is the dilemma of whether a group of pa­
tients who receive an injection of an anesthetic 
should be considered a true control, since deliv­
ery of a local anesthetic can have beneficial ef­
fects for a period exceeding the activity of the 
drug. Second, the natural history of an uncom­
plicated vertebral compression fracture is short; 
it usually resolves by 6 weeks. Only 32% of sub­
jects in the study reported on by Buchbinder et al. 
and 44% of the subjects in the study reported on 
by Kallmes et al. were treated within this time 
frame. Given the short­term follow­up, the influ­
ence of an already healed fracture, a spontaneous 
recovery rate, or another source of pain should 
be considered. Perhaps most troubling is the sig­
nificant difference in crossover rates between the 
treatment and control groups (12% vs. 43%) in the 
study by Kallmes et al. This difference suggests 
patient dissatisfaction with the sham procedure 
that was not fully captured by pain scales.
Given the compelling mechanistic context 
behind vertebroplasty and widespread patient 
satisfaction, careful study design, analysis, and 
long­term outcomes are necessary before this 
well­established technique can be dismissed.
Jeffrey C. Lotz, Ph.D.
University of California, San Francisco 
San Francisco, CA 
lotzj@orthosurg.ucsf.edu
To the Editor: The randomized, controlled tri­
als reported on by Kallmes et al. and Buchbinder 
et al. show no short­term or medium­term bene­
fit of vertebroplasty for the treatment of sympto­
matic osteoporotic vertebral fractures, as com­
pared with a single administration of a local 
anesthetic. We were therefore puzzled that the 
accompanying editorial recommended that phy­
sicians discuss the option of vertebroplasty with 
their patients to allow the latter to make a choice 
that is “based on their values and preferences.”1 
We suggest that it is neither appropriate nor eth­
ical to offer to our patients an intervention that 
is no more effective, is more expensive, and is 
possibly more dangerous than a placebo.
The history of vertebroplasty should remind us 
(again) to be cautious in embracing treatments 
for which the evidence of efficacy is restricted to 
anecdote or observation. Empirical confirmation 
(or refutation) of that which is observed should 
always be sought. The results of these random­
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ized trials should lead to the prompt discontinu­
ation of an ineffective therapy.
Andrew Grey, M.D. 
Mark Bolland, M.B., Ch.B., Ph.D.
University of Auckland 
Auckland, New Zealand 
a.grey@auckland.ac.nz
Weinstein JN. Balancing science and informed choice in de­1. 
cisions about vertebroplasty. N Engl J Med 2009;361:619­21.
Dr. Buchbinder and Colleagues Reply: Per­
sonal anecdote and observational studies are 
biased toward overestimating treatment benefits 
for many reasons.1 Randomized, controlled trials 
are the only truly valid means of establishing or 
refuting the efficacy of vertebroplasty. Our nega­
tive results are supported by the findings of an 
open randomized trial that did not show any bene­
fit of vertebroplasty over usual care at 3 months.2 
All participants in this trial had symptoms for 
8 weeks or less, further refuting the contention 
that benefits are more likely if the treatment is 
given early.
As stated in our article, our trial was more 
than adequately powered to achieve its primary 
efficacy aim of detecting a 2.5­unit advantage of 
vertebroplasty over placebo with respect to the 
pain score. Since the mean effect of vertebro­
plasty has consistently been shown to be close to 
zero in three randomized trials in which partici­
pants in both treatment groups had improvement 
over time, it is doubtful that there would be 
subgroups of patients who would benefit from 
the procedure.3 The only way that a proportion of 
patients could receive a large benefit from verte­
broplasty would be if the condition of another 
subgroup of patients became much worse, a sce­
nario that does not reflect the available data.
The decision by one center to withdraw from 
the trial once government approval for reimburse­
ment became available does not diminish the 
validity of our trial. The other center did not 
formally withdraw and contributed patients over 
the first 2 years. Participation rates of 36% of 
eligible patients in our trial and 30% of eligible 
patients in the trial reported on by Kallmes et al. 
are considered more than acceptable by usual 
trial standards, particularly since both trials in­
cluded a sham procedure. Participants in both 
trials were typical of patient populations seen in 
routine care, and they also shared comparable 
baseline characteristics, including levels of pain 
and disability, with participants in other verte­
broplasty studies. As indicated by the stringent 
selection criteria in both trials, all enrolled pa­
tients had, by definition, unhealed “acute” or 
“subacute” vertebral fractures.
Our trial and the trial reported on by Kallmes 
et al. provide the best evidence we have to date 
regarding the efficacy of vertebroplasty for osteo­
porotic vertebral fractures. Vertebroplasty appears 
to confer no benefit over a sham procedure (not­
withstanding the receipt of local anesthesia) or 
over usual care, and it poses some risk. We con­
cur with Grey and Bolland that it would be nei­
ther appropriate nor moral to offer this treat­
ment in routine care.
Rachelle Buchbinder, M.B., B.S., Ph.D.
Monash University 
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Dr. Kallmes and Colleagues Reply: With re­
gard to the issue of acute fracture raised by Clark 
et al.: two controlled studies that compare verte­
broplasty in acute fractures with medical therapy 
showed no benefit of the procedure at follow­up 
between 6 and 12 weeks.1,2 This lack of benefit 
may reflect the benign natural history of most 
fractures. Vertebroplasty is most appropriately 
performed in patients in whom a course of med­
ical therapy has failed; the duration of this medi­
cal therapy varies, but historically it has ranged 
from 4 to 6 weeks. These persistently painful, 
edematous fractures, such as those in the patients 
enrolled in our trial, may be the ideal fracture 
type in patients in a trial; these fractures have 
not healed and thus probably have a less benign 
natural history than an acute fracture.
Baerlocher et al. suggest that we enrolled pa­
tients with less severe pain than patients in other 
trials. This is false. The baseline pain and dis­
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ability in our patients were equivalent not only 
to all other available, controlled augmentation 
trials,2,3 but also to an eligible but nonenrolled 
cohort at our lead site.4 We would also caution 
that enrollment of only patients with the most 
severe pain might lead to an exaggeration of re­
gression toward the mean, blunting any treat­
ment effect. This tendency may explain the equiv­
alent outcome in the trial of treatment for acute 
fracture reported on by Rousing et al.2
Regarding subtypes of fracture other than the 
acute and severely painful ones described above, 
there remains neither consensus nor compelling 
data to indicate that enrolling only patients with 
fractures with clefts will lead to a positive out­
come in future trials. Not only will such limita­
tions markedly prolong future studies by limiting 
the number of eligible patients, but the presence 
of clefts often is noted only with infusion of 
cement,5 rendering randomization based on the 
presence of cleft imperfect. Further, will there be 
some threshold for the size of the cleft needed 
for enrollment? How will this threshold be de­
termined?
Finally, numerous potential confounding var­
iables may have affected crossover. However, 
crossover was not a prespecified end point. In 
any case, since nearly all crossovers occurred 
after 30 days, crossover did not affect our pri­
mary conclusion that there were no important 
differences in outcomes between the vertebro­
plasty and control groups at 1 month.




Patrick J. Heagerty, Ph.D. 
Jeffrey G. Jarvik, M.D.
University of Washington 
Seattle, WA
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The Editorialist Replies: We should discon­
tinue a treatment when there is convincing evi­
dence that it yields little effect. Unless policies 
are changed so that reimbursement is denied for 
these procedures, doctors will still offer and per­
form vertebroplasty despite what the data sug­
gest. In both studies, controls were active and, in 
fact, they may have been responsible for under­
estimation of the true treatment effect. When 
there is a paucity of level 1 evidence, as in ap­
proximately 50% of health care diagnostic and 
treatment decisions, I believe we must inform pa­
tients, who in most cases will choose the less 
invasive, less risky test or procedure. Patients who 
are given the results of these two studies will 
probably not choose vertebroplasty. Informed 
choice matters. Patient empowerment is the best 
— if not the only — way to change the use of 
ineffective treatments short of refusing to pay for 
these procedures.
James N. Weinstein, D.O., M.S.
Dartmouth Institute for Health Policy and Clinical Practice 
Hanover, NH
Apixaban or Enoxaparin for Thromboprophylaxis
To the Editor: Lassen and colleagues (Aug. 6 
issue)1 state that apixaban and enoxaparin had 
similar efficacy, based on the point estimate for 
the relative risk of all types of venous thrombo­
embolism; this end point was driven mainly by 
asymptomatic distal deep­vein thrombosis. How­
ever, according to established guidelines, non­
inferiority should be shown for major venous 
thromboembolism (the composite of proximal 
deep­vein thrombosis, nonfatal pulmonary em­
bolism, and venous thromboembolism–related 
death).2 The relative risk of major venous throm­
boembolism was 1.25 (95% confidence interval 
[CI], 0.70 to 2.23). Therefore, a relative increase 
in the risk of major venous thromboembolism 
with apixaban of 123% cannot be ruled out. This 
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